C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter D—Drugs for Human UsePart 314—Applications for Fda Approval to Market A New DrugSubpart B—Applications

21 C.F.R. § 314.71 (2026)

Procedures for submission of a supplement to an approved application

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 2009–2023 7citing cases
At a glance

Courts have cited this section in 7 opinions since 2009, 1 of them in the last five years.

(a) Only the applicant may submit a supplement to an application.

(b) All procedures and actions that apply to an application under § 314.50 also apply to supplements, except that the information required in the supplement is limited to that needed to support the change. A supplement is required to contain an archival copy and a review copy that include an application form and appropriate technical sections, samples, and labeling; except that a supplement for a change other than a change in labeling is required also to contain a field copy.

(c) All procedures and actions that apply to applications under this part, including actions by applicants and the Food and Drug Administration, also apply to supplements except as specified otherwise in this part.

[50 FR 7493, Feb. 22, 1985, as amended at 50 FR 21238, May 23, 1985; 58 FR 47352, Sept. 8, 1993; 67 FR 9586, Mar. 4, 2002; 73 FR 39609, July 10, 2008]
The 7 cases that cite 21 C.F.R. § 314.71 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENT.H. v. Novartis Pharm. Corp., 4 Cal. 5th 145 (2017).
cites § 314.71 2×cited by 226 cases
Where it cites § 314.71
“( 21 C.F.R. §§ 314.71 (a), 314.72(a)(2).) The same considerations led this court to unanimously reject a duty of care in O'Neil .”
The case’s holding
A brand-name drug manufacturer owes a duty of care to ensure warning labels are adequate for users of both brand-name and generic bioequivalent drugs.
Later courts cite it for
“in reviewing an order sustaining a demurrer, we examine the operative complaint de novo to determine whether it alleges facts sufficient to state a cause of action under any legal theory.” · 52 citing courts
2
GREENTummino v. Torti, 603 F. Supp. 2d 519 (E.D.N.Y. 2009).
cites § 314.71 2×cited by 15 cases
Where it cites § 314.71
“§§ 355 (c), (d); 21 C.F.R. § 314.71 . Nevertheless, only the drug sponsor can supplement its initial new drug- application.”
The case’s holding
An agency decision is arbitrary and capricious under the Administrative Procedure Act if it results from political interference, bad faith, or departures from normal procedures without reasoned explanation.
Later courts cite it for
“trusted to conduct a fair assessment of the scientific evidence.” · 2 citing courts
3
GREENBartlett v. Mut. Pharm. Co., 659 F. Supp. 2d 279 (D.N.H. 2009).
cites § 314.71 1×cited by 21 cases
Where it cites § 314.71
“21 C.F.R. § 314.71 sets forth the procedures for submitting a supplement to an application.”
The case’s holding
Federal drug-labeling law does not impliedly preempt state-law failure-to-warn claims against a generic drug manufacturer, because federal rules allow post-approval labeling changes that could have strengthened the warnings.
Later courts cite it for
“the fda's remarks in proposing and promulgating these regulations” · 2 citing courts
4
NO FLAGAll. Hippocratic Med. v. FDA, No. 23-10362, 2023 WL 2913725 (5th Cir. Apr. 12, 2023).
cites § 314.71 1×cited by 0 cases
Where it cites § 314.71
“We also recognize that it’s somewhat of a strain to say that the 2016 Major REMS Changes and 2021 Petition Denial (and related changes) altered the regulatory landscape to such a degree that the prior rule is only now “worth challenging” when it otherwise might “not have been.”
5
NO FLAGSmith v. GE Healthcare Inc, No. 3:19-cv-00492, 2019 WL 4565246 (W.D. La. Sept. 4, 2019).
cites § 314.71 1×cited by 0 casesunknown
Where it cites § 314.71
“21 C.F.R. § 314.71 (a). GE Healthcare was the NDA applicant for Omniscan.”
6
NO FLAGLewis v. GE Healthcare Inc, No. 5:19-cv-00490 (W.D. La. Mar. 13, 2020).
cites § 314.71 1×cited by 0 casesunknown
Where it cites § 314.71
“21 C.F.R. § 314.71 (a). GE Healthcare was the NDA applicant for Omniscan.”
7
GREENBartlett v. Mut. Pharm., 2009 DNH 144 (D.N.H. 2009).
cites § 314.71 1×cited by 0 cases
Where it cites § 314.71
“and then 10 21 C.F.R. § 314.71 sets forth the procedures for submitting a supplement to an application.”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
200920162023

One bar per year. Tallest: 3 cases in 2009. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
W.D. La.2D.N.H.25th Cir.1Cal.1E.D.N.Y1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com